Peripheral Nerve Schwannoma: A Review of Varying Clinical Presentations and Imaging Findings.

A schwannoma or neurilemmoma is a benign, isolated, noninvasive, and encapsulated tumor originating from Schwann cells of the peripheral nerve sheath. The incidence of a schwannoma occurring in the foot and ankle is rare, with prevalence rate of 1% to 10%. Schwannomas have no sex predilection, and they commonly occur in patients in their fourth decade. Malignant transformation of benign schwannoma is unusual; however, it is important to note that malignant variants of schwannomas do exist and account for about 5% to 10% of all soft tissue sarcomas. We present 3 cases of benign schwannoma in the lower extremity. All 3 patients presented with varying clinical symptoms, including pain, paresthesia, weakness, and a palpable mass. A schwannoma was eventually diagnosed in all 3 patients. We discuss and review the known entities of peripheral nerve schwannoma and describe the clinical and imaging findings and therapeutic strategies for treating and diagnosing peripheral nerve schwannoma.

Magnetic resonance imaging, computed tomography, and radiographic correlation of nonunion of the posteromedial tubercle of the talus: a case report.

Fracture of the posteromedial tubercle of the talus is an uncommon injury that is often missed on plain radiographs. In the present report, we describe the case of an adult male with a chronic nonunited fracture of the medial tubercle of the posterior process of the talus after having undergone clinical and radiographic evaluation in a community hospital emergency department. A review of the computed tomographic, magnetic resonance imaging, and plain film radiographic findings associated with nonunion of the posteromedial tubercle of the talus is also presented.

Ciclopirox 8% nail lacquer topical solution for the treatment of onychomycosis in patients with diabetes: a multicenter, open-label study.

BACKGROUND: An open-label, noncomparative study was conducted to assess the safety and efficacy of ciclopirox 8% nail lacquer topical solution in patients with type 2 diabetes mellitus. METHODS: Forty-nine diabetic patients with distal subungual onychomycosis were treated once daily for 48 weeks with ciclopirox 8% nail lacquer, a topical nail solution approved for the treatment of patients with mild-to-moderate onychomycosis. RESULTS: Treatment resulted in clinical improvement in 63.4% of patients. Most patients (85.7%) had a mycologic outcome of improvement or cure, with 54.3% attaining mycologic cure. Consideration of mycologic and clinical outcomes generated a treatment outcome of improvement, success, or cure in 84.4% of patients. Moreover, patients experienced improvement in the diseased area of the nail (63.4%), nail surface (56.1%), nail color (48.8%), and nail thickness (65.9%). Ciclopirox 8% nail lacquer was safe, with treatment-related adverse events limited to infection in one patient, which resolved in 15 days; the patient completed the study. No treatment-related serious adverse events were observed. CONCLUSION: Ciclopirox 8% nail lacquer is a safe and effective treatment for distal subungual onychomycosis in patients with type 2 diabetes mellitus receiving insulin or oral hypoglycemic therapy.

Cutaneous larva migrans: the creeping eruption.

Cutaneous larva migrans (CLM) is the most common tropically acquired dermatosis. It is caused by hookworm larvae, which are in the feces of infected dogs and cats. The condition occurs mainly in the Caribbean and New World, and anyone walking barefoot or sitting on a contaminated beach is at risk. Ancylostoma braziliense and Ancylostoma caninum are the most common hookworms responsible for CLM. The lesions, called creeping eruptions, are characteristically erythematous, raised and vesicular, linear or serpentine, and intensely pruritic. The conditions respond to oral and/or topical application of thiabendazole. Humans become an accidental dead-end host because the traveling parasite perishes, and its cutaneous manifestations usually resolve uneventfully within months.